Background & aims: Colonoscopy is the preferred screening test for colorectal neoplasia; the fecal occult blood test (FOBT) detects neoplasias with low levels of sensitivity. Computed tomographic colonography detects neoplasias with high levels of sensitivity but involves exposure to radiation. We investigated whether magnetic resonance colonography (MRC) can be used to screen for colorectal adenomas and cancers.
Background & aims: Colonoscopy is the preferred screening test for colorectal neoplasia; the fecal occult blood test (FOBT) detects neoplasias with low levels of sensitivity. Computed tomographic colonography detects neoplasias with high levels of sensitivity but involves exposure to radiation. We investigated whether magnetic resonance colonography (MRC) can be used to screen for colorectal adenomas and cancers.
Methods: We analyzed data from 286 asymptomatic adults (40-82 years old) who underwent 3 Tesla MRC and colonoscopic examinations on the same day. FOBT was performed before bowel preparation. Colonoscopists were initially blinded to the findings on MRC and unblinded after withdrawal from the respective segments. Sensitivities for adenoma and per-patient sensitivities and specificities were calculated based on the unblinded results of colonoscopy.
Results: We detected 133 adenomas and 2 cancers in 86 patients; 37 adenomas were Z 6 mm, and 20 adenomas were advanced. Sensitivities of MRC and colonoscopy for adenomas Z 6 mm were 78.4% (95% confidence interval [CI] , 61.8-90.2) and 97.3% (95% CI, 85.8-99.9); for advanced adenomas these values were 75% (95% CI, 50.9-91.3) and 100% (95% CI, 83.2-100.0), respectively. MRC identified 87.1% (95% CI, 70.2-96.4), colonoscopy 96.8% (95% CI, 83.3-99.9), and FOBT 10.0% (95% CI, 2.1-26.5) of individuals with adenomas Z 6 mm and 83.8% (95% CI, 58.6-96.4), 100% (95% CI, 81.5-100.0), and 17.6% (95% CI, 3.8-43.4) of individuals with advanced neoplasia. Specificities of MRC, colonoscopy, and FOBT for individuals with adenomas Z 6 mm were 95.3% (95% CI, 91.9-97.5), 96.9% (95% CI, 93.9-98.6), and 91.8% (95% CI, 87.6-94.9), respectively.
Conclusion: 3 Tesla MRC detects colorectal adenomas Z 6 mm and advanced neoplasia with high levels of sensitivity and specificity. Although MRC detects color-ectal neoplasia with lower levels of sensitivity than colonoscopy, it strongly outperforms one-time FOBT.
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Use of a single-balloon enteroscope compared with variable-stiffness colonoscopes for endoscopic retrograde cholangiography in liver transplant patients with Roux-en-Y biliary anastomosis
Background: Endoscopic retrograde cholangiography (ERC) is technically challenging in liver transplant patients with Roux-en-Y biliary anastomosis. The optimal endoscope for such cases remains unknown.
Objective: Compare efficacy and safety of performing ERC in liver transplant patients with Roux-en-Y biliary anastomosis by using an adult colonoscope (AC), a pediatric colonoscope (PC), and a single-balloon enteroscope (SBE).
Design: Retrospective chart review.
Setting: Tertiary-care referral center.
Patients: Liver transplant patients with Roux-en-Y biliary anastomoses.
Intervention: ERC with AC, PC, and SBE.
Main outcome measurements: Rates of reaching the afferent limb and biliary anastomosis; rates of cannulation; rates of diagnostic, therapeutic, and procedural success; and number of adverse events.
Results: Ninety patients underwent 199 ERCs from 2002 to 2012; 86 with an AC, 55 with a PC, and 58 with an SBE. Biliary cannulation and diagnostic, therapeutic, and procedural success rates were all significantly higher with an SBE than with a PC. Among patients undergoing the initial ERC, no statistical difference was found among SBE, the PC, and an AC. However, the rate of procedural success with SBE during initial ERC over the last 4 years has increased. Of 25 total failures with ACs, exchange for SBEs resulted in procedural success in 4 of 4 attempts. Of 22 failures with a PC, exchange for an SBE resulted in success in 3 of 4 cases. Of 4 failures with SBE exchange in 6 cases (4 to AC, 2 to PC), SBE resulted in success in only 1. No adverse events occurred directly related to type of endoscope.
Limitations: Retrospective study, single center, lack of standardized approach to selection of endoscopes, uncontrolled variables (general anesthesia, learning curve).
Conclusion:
In liver transplant patients with Roux-en-Y anatomy, rates of biliary cannulation, therapeutic success, and procedural success are higher with use of an SBE than with a PC and tend to be higher compared with use of an AC among the overall cohort. Use of an SBE and procedural success rates with SBEs have increased over the last 4 years. Failed cases with either an AC or PC can be completed if exchanged for an SBE.
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Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study
Christine Rungoe, Saima Basit, Mattis Flyvholm Ranthe, Jan Wohlfahrt, Ebbe Langholz, Tine Jess Background: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder. Systemic inflammation increases the risk of atherosclerosis and ischaemic heart disease (IHD).
Objective: To examine the impact of IBD, including its duration and treatment, on the risk of IHD.
Methods: In a nationwide population-based cohort of 4.6 million Danes aged Z 15 years, we compared people diagnosed with IBD during 1997-2009 (n = 28 833) with IBD-free individuals. Subjects with IHD were identified in the National Patient Register. Using Poisson regression, we estimated the incidence rate ratios (IRRs) for IHD with 95% CI with adjustment for age, gender, socioeconomic status, calendar year and use of drugs for comorbidities.
Results:
A markedly increased risk of IHD was seen within the first year after IBD diagnosis (IRR = 2.13 95% CI, 1.91-2.38). During 1-13 years of follow-up after IBD diagnosis, the risk of IHD was 1.22 (95% CI, 1.14-1.30). The risk of IHD was lower among patients with IBD using 5-aminosalicylic acids (IRR = 1.16; 95% CI, 1.06-1.26) than among non-users (IRR = 1.36; 95% CI, 1.22-1.51) (P = 0.02), in particular among oral corticosteroid users, used as a proxy for disease severity. Likewise patients treated surgically or with thiopurines and tumour necrosis factor a antagonists tended to have reduced IRRs for IHD.
Conclusions:
The risk of IHD was highest in the first year after IBD diagnosis, possibly owing to ascertainment bias. The increased long-term risk of IHD in IBD may be related to chronic inflammation, and interventions reducing the inflammatory burden may attenuate this risk. Background: Constipation is a common condition for which PEG 3350 is an established treatment and prucalopride has recently been approved for this indication.
Aims: To compare the efficacy, safety and impact on quality of life (QoL) of PEG 3350 plus electrolytes (PEG 3350 + E) vs. prucalopride in females with chronic constipation (CC) in whom laxatives have previously failed to provide adequate relief.
Methods: In this single-centre, randomised, double-blind, double-dummy study, patients with CC [< 3 spontaneous complete bowel movements (SCBM)/week] remained in a controlled environment and received either a 26 g split dose of PEG 3350 + E (N = 120) or 1-2 mg prucalopride (N = 120) daily for 28 days following a 14-day run-in period. The primary endpoint was the proportion of patients having Z 3 SCBMs during the last treatment week.
Results: Non-inferiority of PEG 3350 + E to prucalopride was demonstrated in the per-protocol population [difference, 10.1% (66.67% vs. 56.52%), 97.5% lower confidence interval (CI) -2.7%, above the preset margin of -20%] and approached superiority in the modified intent-totreat population (difference, 9.8%, 97.5% lower CI, -3.1%). Statistically significant differences in favour of PEG 3350 + E were observed for most secondary variables (bowel movements, stool weight, consistency, time to next SCBM, patient perception of straining and completeness of defecation). Colonic transit time was dramatically reduced in both arms. Both treatments were well tolerated.
Conclusion: PEG 3350 + E was at least as effective as and generally better tolerated than prucalopride as a treatment for chronic constipation in this study population (NCT01251822; http://www.clinicaltrials.gov).
Alimentary Pharmacology & Therapeutics 2013; 37:876-886.
Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C
The aim of this retrospective cohort study was to assess the cumulative development incidence and predictive factors for malignancies after the termination of interferon (IFN) therapy in Japanese patients for hepatitis C virus (HCV). A total of 4302 HCV-positive patients treated with IFN were enrolled. The mean observation period was 8.1 years. The primary outcome was the first onset of malignancies. Evaluation was performed using the Kaplan-Meier method and Cox proportional hazard analysis. A total of 606 patients developed malignancies: 393 developed hepatocellular carcinoma (HCC) and 213 developed malignancies other than HCC. The cumulative development rate of HCC was 4.3% at 5 years, 10.5% at 10 years, and 19.7% at 15 years. HCC occurred significantly (P < 0.05) when the following characteristics were present: advanced histological staging, sustained virological response not achieved, male sex, advanced age of Z 50 years, total alcohol intake of Z 200 kg, and presence of type 2 diabetes (T2DM). T2DM caused a 1.73-fold enhancement in HCC development. In patients with T2DM, HCC decreased when patients had a mean hemoglobin A1c (HbA1c) level of <7.0% during followup (hazard ratio, 0.56; 95% confidence interval, 0.33-0.89; P = 0.015). The cumulative development rate of malignancy other than HCC was 2.4% at 5 years, 5.1% at 10 years, and 9.8% at 15 years. Malignancies other than HCC occurred significantly when patients were of advanced age of r 50 years, smoking index (package per day Â year) was Z 20, and T2DM was present. T2DM caused a 1.70-fold enhancement in the development of malignancies other than HCC.
Conclusion: T2DM causes an approximately 1.7-fold enhancement in the development of HCC and malignancies other than HCC in HCV-positive patients treated with IFN. In T2DM patients, maintaining a mean HbA1c level of <7.0% reduces the development of HCC.
Hepatology 2013; 57:964-973.
Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies
Austin Duffy, Julia Wilkerson, Tim F. Greten
The presence of cirrhosis increases the potential risk of hemorrhage for patients with hepatocellular carcinoma (HCC). We evaluated the relative risk for hemorrhage in patients with HCC treated with antiangiogenic agents. We performed a systematic review and meta-analysis of antiangiogenic studies in HCC from 1995 to 2011. For nonrandomized studies we compared bleeding risk with other HCC single-arm studies that did not include an antiangiogenic agent. To separate disease-specific factors we also performed a comparison analysis with renal cell cancer (RCC) studies that evaluated sorafenib. Sorafenib was associated with increased bleeding risk compared to control for all grade bleeding events (odds ratio [OR] 1.77; 95% confidence interval [CI] 1.04, 3.0) but not grade 3-5 events in both HCC and RCC (OR 1.46; 95% CI, 0.9, 2.36; P = 0.45). When comparing the risk of bleeding in single-arm phase 2 studies evaluating antiangiogenic agents, this risk for all events (OR 4.34; 95% CI, 2.16, 8.73) was increased compared to control.
Conclusion: This analysis of both randomized and nonrandomized studies evaluating an antiangiogenic agent in HCC showed that whereas the use of sorafenib was associated with an increased risk of bleeding in HCC, this was primarily for lower-grade events and similar in magnitude to the risk encountered in RCC. Background & aims: Extrapyramidal and cerebellar symptoms belong to the most prominent features of episodic hepatic encephalopathy, and usually decrease upon ammonia-lowering therapy. Rapidly progressing parkinsonian symptoms, which are unresponsive to treatment of hepatic encephalopathy, indicate cirrhosis-related Parkinsonism. This study aims at analyzing the prevalence of cirrhosis-related Parkinsonism in patients with liver cirrhosis, and to study the functional status of the striatal dopaminergic system in these patients.
Methods: 214 patients with liver cirrhosis who were consecutively seen at the out-patient clinic for liver transplant candidates and/or at the transplantation wards at Hannover Medical School, between 1 August, 2008 and 31 March, 2011, underwent a standardized neurological examination while on the waiting list or immediately after liver transplantation. Single photon emission computer tomography (SPECT) using 123 I-beta-CIT, for the evaluation of the striatal dopamine transporter function, and 123 I-IBZM for the evaluation of the striatal dopamine D2 receptor availability, was performed in 6 patients with cirrhosis-related Parkinsonism.
Results: Cirrhosis-related Parkinsonism was diagnosed in 9 of 214 patients (4.2%). SPECT revealed significantly decreased dopamine receptor availability in 5 of 6 patients studied, and significantly decreased dopamine transporter availability in 3. Levodopa improved motor dysfunction in two of four patients treated, although only temporarily. Incomplete recovery was observed in two patients after liver transplantation.
Background & aims: Non-alcoholic fatty liver disease (NAFLD) is associated with a twofold greater risk of developing cardiovascular disease. Despite this, little is known about the effect of NAFLD upon cardiac function, limiting our ability to identify therapeutic strategies. This study aimed to address this by defining the effect of NAFLD on cardiac function, structure, and metabolism.
Methods: Nineteen adults with NAFLD were age-, sex-, and BMI-matched to healthy controls without liver or metabolic disease. Cardiac structure and function were assessed using high-resolution cardiac MRI and tagging at 3.0 T. High-energy phosphate metabolism was assessed using 31 P-magnetic resonance spectroscopy to measure the PCr/ATP ratio.
Results: Adults with NAFLD had significantly thicker left ventricular walls at systole (14±3 vs. 12±2 mm; P < 0.01) and diastole (8±1 vs. 7±1 mm; P < 0.01) than those without fatty liver and showed decreased longitudinal shortening (14±3 vs. 17±3%; P < 0.01). The eccentricity ratio was significantly higher in the NAFLD group (1.1±0.2 vs. 0.9±0.2 g/ml; P < 0.01) indicating concentric remodelling. Peak whole wall strain was higher in the NAFLD group (19±2 vs. 17±3%; P < 0.01), as was peak endocardial strain (28±4 vs. 22±5%; P < 0.01). Cardiac metabolism, measured by PCr/ATP ratio, was not altered in NAFLD (1.8±0.3 vs. 1.9±0.3; P = 0.36).
Conclusion: Significant changes in cardiac structure and function are evident in adults with NAFLD in the apparent absence of metabolic changes or overt cardiac disease. Clinicians should continue to explore therapies to improve cardiac function as a means to modify the excess risk of cardiovascular disease associated with NAFLD.
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